Poor DryBones, I can’t fix stupidIt’s never been about Ryplazim, it’s always been about PBI-4050, and around the year 2020 is when PBI-4050 should be approved for sale to Alstrom patients in the U.K. under their Early Access Program and that’s when Prometic should really take off; I have posted those same words soooooo many times. Please learn to read, then please learn to comprehend what is written... I won’t always be around to guide you through your “troubles” in life.
Ryplazim is good and will “bump” the sp, but PBI-4050 will be the major catalyst imo.
Ever notice why PL, the management team, and even Thomvest refer to 2024?
By 2024 PBI-4050 should start to “mature” and settle into the marketplace, that’s why.
When fully mature in the explored indications Ryplazim should be a $15 Billion dollar market. When fully mature in indications PBI-4050 should top in excess of $50 Billion dollars. See the difference Mr. DryBone? Stop thinking small in life is my advice to you. Small keeps you in the rear view mirror of life, just ask Mr. G.